Open Access DOI:10.23937/2643-4563/1710019
Usefulness of P16 and KI67 Immunostaining in Cervical Smear Cytology in Guatemalan Women: A Cross-Sectional Study
Alberto Garcia, MD, PhD, Angel Velarde, MD, MSCE, Francisco Quereda, MD, PhD, Jaume Ordi, MD, PhD, Orlando Rodas, MD, PhD, Erick Soch, MD, H Arturo Morales, MD, Federico Nave and Carlos Lopez, MD
Article Type: Original Research | First Published: October 18, 2019
Conventional cytology is an economic method for screening abnormalities in cervical smears, but with implications in false positive and false negative as compared to better detection of transformed cells with the Dual staining P16/KI67 proteins in cervical smears, therefore, we evaluate the validity and reproducibility of cytology with double staining of P16 and KI67 as compared to conventional cytology in cervical smears. Participants were 210 Guatemalan women with abnormalities in conventional...
Open Access DOI:10.23937/2643-4563/1710018
Immunotherapy with the Vaccine Based On the Canine Neurotropic Virus (CIMT-54) For the Treatment of Cancer
Hugo Ramiro Segura-Puello, Juan Sebastian Segura Charry, Diana Milena Munoz-Forero, Diana Lorena Nieto Mosquera and Andrea Catalina Villamil-Ballesteros
Article Type: Original Article | First Published: October 16, 2019
At Cancer Research Laboratory of Manuela Beltran University (UMB), research was carried out with the design and development of the CIMT-54 biological vaccine: A combination of oncotropic virus + amino acids as adjuvants, which act directly on the tumor cell, preventing the reproduction of metastases to other organs and preventing the attack on healthy cells of the organism. The results at preclinical level suggested that the CIMT-54 vaccine is not cytotoxic; and on the other hand, in the studies...
Open Access DOI:10.23937/2643-4563/1710017
Pharmacokinetics of Oxaliplatin in a Hemodialysis Patient with Metastatic Colon Cancer
Yoshiaki Nagatani, Yoshinori Imamura, Tsutomu Nakamura, Kazuhiko Yamashita, Mamoru Okuno, Hiroyuki Yasui, Jun Hiraoka, Riho Niigata, Keiji Kono, Yasuko Hyogo, Hirotaka Suto, Kei Takenaka, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota and Hironobu Minami
Article Type: Original Article | First Published: September 16, 2019
Although oxaliplatin is one of the main anticancer agents used against colorectal cancer, data on the pharmacokinetics of oxaliplatin in patients on hemodialysis are limited. In this case study, we evaluated the pharmacokinetics and safety of oxaliplatin in a patient on hemodialysis treated for colon cancer. A 68-year-old Japanese woman receiving chronic hemodialysis was treated for metastatic colon cancer with modified FOLFOX6 plus bevacizumab every 2 weeks. Initial oxaliplatin dose was reduc...
Open Access DOI:10.23937/2643-4563/1710016
Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile
Raiza Ruiz Lorente, Sayly Alfonso, Yamilka Sanchez, Carmen Elena Viada, Ramon Ortiz, Mayelin Troche, Meylan Cepeda, Ana Rosa Vals, Leticia Cabrera, Annia Gorte, Delmis Maira Batista, Milagros Domenech, Jessica Garcia Viamontes, Conrado Ramos Mico and Mayra Ramos Suzarte
Article Type: Review Article | First Published: July 29, 2019
The EGF receptor is over expressed in tumors of epithelial origin and is associated with a poor prognosis of the disease. An Expanded Clinical Access Program was carried out, in which patients with cervical uterine cancer in advanced stages of the disease without another therapeutic alternative were treated with nimotuzumab, anti-epidermal growth factor receptor humanized monoclonal antibody to evaluate the safety and efficacy of this therapy. Seventy-five patients with confirmed histological di...
